Anthropic has appointed Vas Narasimhan, CEO of Novartis, to its board of directors, strengthening its leadership in healthcare and AI governance. Vas Narasimhan brings extensive experience in global medicine development, regulatory affairs, and large-scale pharmaceutical innovation. At Novartis, he has overseen the development and approval of more than 35 novel medicines across multiple therapeutic areas. 

His addition to Anthropic reflects the company’s focus on responsible AI, safety standards, and strong governance frameworks. The appointment is expected to support Anthropic’s mission of building safe and reliable artificial intelligence systems at scale. With this move, Anthropic strengthens its board with deep expertise in healthcare and global regulatory environments. The collaboration highlights increasing convergence between biotechnology leadership and advanced AI governance as companies prioritize safe deployment.

Industry observers note that Vas Narasimhan’s experience in highly regulated healthcare markets could help Anthropic refine risk management practices, align with global compliance expectations, and scale AI systems responsibly across critical sectors including medicine, research, and enterprise applications worldwide with strong long-term strategic value creation impact.